A lab-made tanning compound that also affects appetite and sexual arousal.
Generally not recommended — a safer, FDA-approved alternative (PT-141) exists for sexual function.
Health authorities in several countries have warned of serious risks, including melanoma and heart events. The highest-risk compound in this guide.
What it is
Melanotan II is a synthetic version of a hormone called alpha-MSH, but unlike the more refined compounds developed from it (including PT-141 in this guide), it activates multiple melanocortin receptors simultaneously without selectivity. It was originally developed as a sunless tanning agent — and it does produce reliable, potent skin darkening. During those early studies, researchers observed that it also caused unexpected sexual arousal and appetite suppression as side effects, via a different receptor (MC4R). That discovery eventually led to the development of the more targeted, FDA-approved PT-141. Melanotan II itself was largely abandoned as a pharmaceutical development project. It is not FDA-approved, not approved by any national pharmaceutical regulator anywhere in the world, and has been the subject of explicit safety warnings from the UK, Australian, and Irish health authorities citing melanoma risk, heart events, and psychiatric effects. If sexual function is the goal, PT-141 is the safer and approved option.
Potential benefits
Skin Pigmentation (Tanning)
Reliable and potent melanin increase — documented. Also causes changes to existing moles and new mole formation — clinically concerning.
Sexual Arousal (via MC4R)
Documented and potent effect on sexual arousal and erectile function — well-established in clinical studies. This effect led to PT-141 development. If sexual function is the goal, PT-141 is the more appropriate and FDA-approved option.
Appetite Suppression
MC4R activation reduces appetite. Pharmacologically real but uncontrolled.
Risks and contraindications
Common Side Effects (documented)
- Severe nausea and vomiting — extremely common
- Facial flushing — frequent and pronounced
- Spontaneous / prolonged erections (priapism) — may require medical intervention
- Extreme fatigue and sedation
- Darkening / changes to existing moles
- New mole formation — documented
- Hypertension
Serious Documented Risks
- Melanoma risk: regulatory warnings issued in UK, Australia, Ireland
- Rhabdomyolysis: cases reported
- Myocardial infarction: cases reported
- Psychiatric effects: anxiety, mood changes, mania/psychosis-like symptoms
Contraindications / cautions
- Cancer history · Many/atypical moles · Skin cancer history
- Cardiovascular disease · Hypertension · History of MI/stroke
- Psychiatric history · Pregnancy · Under 18
Research reality
Melanocortin receptor pharmacology is well characterized in animal research. The effects on pigmentation, sexual function, and appetite are understood at a mechanistic level.
Limited Phase 1 and 2 studies were conducted before the pharmaceutical development program was largely discontinued in favor of PT-141. Documented serious adverse events in both the trials and post-market observation are the most important data points.
Explicit public health warnings have been issued by the UK's MHRA, Australia's TGA, and Ireland's HPRA, specifically naming melanoma risk, cardiovascular events, and psychiatric effects. This level of coordinated, multi-country regulatory warning language is unusually strong and should be taken seriously.
The highest-risk compound in this guide. The pharmacological effects are real and potent — but the documented adverse events are serious. An FDA-approved alternative (PT-141) exists for its primary use case. The risk-benefit case for Melanotan II is very difficult to justify in most situations.